Message to RC on possible sale new

Ron

Don't let your ego cloud your judgment

Time to seriously consider to serious M&A offers.

Your answer to recent financial news from a major investor is telling the other investors that the management team and BoD won't let go of their "jobs". You won't let go of "your" company no matter what the offer is.
It brings questions whether you have all the investors' best interest at heart - your fiduciary duty.

Maybe there is a true rationale for remaining independent.
But there is MUST be a share-price-threshold that you/BoD are willing to consider a M&A deal.

A "little" Investor who loves ACOR.

PS. I will let others who are shareholders opine.
We know you read CP daily.

 

This is the plan: pretend to hold off and rant to the Street about how you are not for sale. Stock price goes up, and you sell on the 'sweetest deal'. This was the plan all along. That hedge fund will influence others investors who await a sale and hope to make money. IF RC FIGHTS THIS, HIS STOCK PRICE WILL PLUMMET BIGLY.
Folks - this is fact. It is a factual as Chris Christie sitting on the beach after he closed the parks. Therefore, the suggestion we have is to put the pieces together - one mistake after the other, people layed off, therefore cut expenses, streamline, and then get a hedge fund to strike. It was all in the original plan.

Signed sizable investor

 

Updated: Acorda shares surge as a big investor pushes it to the auction block

Looking to score a quick return, one of Acorda’s biggest shareholders $ACOR wants to call a time-out on the biotech’s death defying high wire act and roll out a safety net — for investors.

Scopia Capital Management filed notice with the SEC today that it has sent Acorda CEO Ron Cohen a letter outlining its call for a strategic review — including a hard push for a company auction. While counting itself a longtime admirer of Acorda, Scopia concluded that while the company has the cash needed to move forward “continuing to pursue an independent strategy presents significant risk for shareholders.”

Scopia controls 16.5% of Acorda’s shares, which surged 5% this morning as the buyout buzz word circulated. And Scopia added more than a million shares as the news about a possible sale hit.

Acorda was recently forced to restructure after the company lost a key patent decision covering its cash cow, the MS drug Ampyra. It’s appealing the decision, but with the distinct possibility that generic competition is looming, the biotech slashed more than 100 jobs in April and circled the wagons around CVT-301, now under review at the FDA.

The idea at Acorda is that if they do lose patent protection next summer, the sales force can move seamlessly on to the new drug. But even in the best of all possible worlds, few developers can rely on anything being seamless in R&D and at the FDA. And Scopia doesn’t like this position at all.

From the letter:

While we have been supportive of the Company’s strategy to this point, we believe it is now time to sell the Company. Had the Company prevailed in the Ampyra litigation, Acorda would have been a unique company with a path to $1B in revenues and significant standalone value. Unfortunately, the Company was unsuccessful, and it has now crossed the Rubicon. In 2018 the business will revert to burning cash with a levered balance sheet and no clear timeline to return to profitability. These are treacherous waters. At the same time, recent acquisitions of both Cynapsus ($624M) and NeuroDerm ($1.1B) speak to the strategic value of late stage assets in Parkinson’s disease. Acorda is a more valuable acquisition candidate than either of these companies.

Inbrija (formerly CVT-301) should launch next year and treat a real unmet need in advanced Parkinson’s disease. While we believe in the value of this drug, it will take time to launch and will likely only replace Ampyra revenues. Tozadenant may succeed in Phase 3 next year, or it might fail. The path to a highly profitable, multi-product independent company will be solely determined by this binary event. That is a lot of development risk for shareholders to bear.

Acorda, though, says it doesn’t agree. In a reply posted with the SEC, the company said a sale now would simply destabilize the company and leave shareholders shortchanged.

Acorda has a market cap today of a little more than a billion dollars.

 

Updated: Acorda shares surge as a big investor pushes it to the auction block

 

While we have been supportive of the Company’s strategy to this point, we believe it is now time to sell the Company. Had the Company prevailed in the Ampyra litigation, Acorda would have been a unique company with a path to $1B in revenues and significant standalone value. Unfortunately, the Company was unsuccessful, and it has now crossed the Rubicon. In 2018 the business will revert to burning cash with a levered balance sheet and no clear timeline to return to profitability. These are treacherous waters. At the same time, recent acquisitions of both Cynapsus ($624M) and NeuroDerm ($1.1B) speak to the strategic value of late stage assets in Parkinson’s disease. Acorda is a more valuable acquisition candidate than either of these companies

 

LOL, the BS is flying here tonite, probably driven by a certain outside investor(s) pushing for the sale. However Leadership takes the long term strategic viewpoint with serious fiduciary responsibility. Moreover, Leadership is not buying these flawed posts and fully expects the CVT rollout (and others in the pipeline) to be a great success with revenue and ROI on record setting rebound. Also note Wallstreet SMEs see the future of ACOR as strong buy.

 

As ACOR now delegated Felicia and Tierney to make replies on CP? Or is it Soon and Andrew? You guys should be working and not surfing CP.

Too bad, it is a good company that should be sold at this point, before it implodes.

 

SELL SELL SELL

 

LEADERSHIP DOES NOT HAVE TIME TO "SURF" CP ! ! !

 

Then get off CP, and get to work; make us investors some money for a change. I am tired of the yo-yo stock performance over the past 9 years, and certainly the past 2 years have been a true disappointment. (If you Leadership collect ANY bonus this year, there will be an investor's revolt of unparalleled proportions)

 

The Street sees no value and they are now voicing it. RC will drive this company into a hole b4 he sells. Egomaniac with no business sense.

 

The field sales force will be cut by end year. That is in the plan given generic Ampyra. More cuts inside to follow. They will show this as a 'gesture' given that investors have ben shit on.

 

Time to Tweet BS, time to post BS here as well. We all know who is on here defending a weak ass pipeline all the time.

 

LEADERSHIP HAS NO IDLE TIME TO POST STUPID IDIOTIC RESPONSES TO STUPID IDIOTIC POSTS ! !

Our stock will do quite well. Wall Street is bulking up on ACOR. Long term gains will manifest. Token cutbacks will be more than offset by recruitment of new stars.

 

Yes up to $70 right. LMAO!!!!!!!!!!!!!!!!!!!!!!!!!!

 

The above is another example of the brain farts posting here. No doubt a disgruntled employee. If you don't trust Leadership then you might consider either switching careers or joining another company if still here. Fact is ACOR will do very well.

 

Now that you are done insulting everyone with a different opinion than yourself, you might want to think about putting up or shutting up.

The facts are:
People are leaving
ACOR is at the same value from 7 years ago
Investors are pushing for a sale which is not a sign of faith in leadership or the pipeline.
ACOR has over paid for assets and under estimated both time and cost to advance them
ACOR is losing its ONLY revenue stream soon

You on the other hand keep posting your "opinion" on the future despite facts.

Either show progress or STFU. Facts are not on your side.

 

Smart ! Playing the right game. Thursday and Friday the stock surged at the close - this is the time the institutional investors step up when they are looking at a stock with tremendous upside. Ron knows exactly how to play the game. Look we are absolutely on the right track with an incredible upside - by following Ron's lead. Acordians Unite !! We Are The Champions !! No Time For Losers For We Are The Champions !!

 

You must work for CNN!

Surged at the close! You are still below $22, which is where you were days ago. At least lie convincingly if you are going to spread BS to bolster your delusions.

 

Let us reiterate: ACOR is a long-term play and will reward faithful shareholders immensely. Your post nitpicks about the daily close over a two day period...how ridiculous !!! Leadership has a proven strategy that it is executing with precision. If you feel uncomfortable owning ACOR then by all means sell it. The market for ACOR is much bigger than you can imagine !

Best of luck at your next employee.